The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...

As the first second-generation INSTI approved for newborns with HIV, this approval allows for a simpler, more robust antiretroviral therapy regimen than existing standard of care.

Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...

The U.S. Food ​and Drug Administration has approved ‌Gilead Sciences' once-daily oral combination pill for treatment of ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. NAKURU, KENYA - 2026/03/26: A healthcare worker fills a syringe with a dose of lenacapavir, ...

Postdoctoral researcher Archana Joon at Albert Einstein College of Medicine studies how herpes simplex virus reshapes the ...

Second Study in ACTG’s Small Clinical Trials Advancing HIV Remission and Cure ProgramCHAPEL HILL, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and ...

For National Faith HIV & AIDS Awareness Day, NMAC’s Jennifer Moore Phillips argues that trusted, accountable faith ...